Seres Therapeutics’ ambitions to treat ulcerative colitis with a microbiome drug were dealt a setback as its experimental therapy failed in Phase 2 testing. The company plans a “rigorous scientific analysis” to assess what happened and to determine the next steps for the program.
Close the Clinical Gap, Discover the Next Generation of Microbiome-based Therapeutics, and Establish New Partnerships to Accelerate Your Research The most comprehensive forum for microbiome drug developers, the Microbiome Movement – Drug Development Summit returns for its sixth iteration! We will continue to unite forward-thinking researchers from the biopharmaceutical and academic communities to pursue the causal role of …
Founded in 2014, MaaT Pharma is pushing two therapies through clinical trials that are designed improve survival for patients with blood cancers and other diseases. Despite high-profile hiccups, the field of microbiome therapy remains attractive to investors.